Regeneron Pharmaceuticals, a biotechnology company, has announced a strategic collaboration with Truveta and its network of U.S. health systems to enhance innovation in healthcare through data-driven discovery. As part of this collaboration, Regeneron is investing $119.5 million in Truveta’s Series C financing and launching the Truveta Genome Project. This initiative aims to sequence up to 10 million de-identified patient volunteers and link their genomic data with electronic health records. The project is expected to generate insights into the connection between genetics and health, potentially leading to the development of new therapies and improved healthcare delivery.
The Regeneron Genetics Center will lead the sequencing efforts, leveraging its expertise in genomic research and drug discovery. The resulting dataset, which integrates Truveta's de-identified medical database of more than 120 million patients, has the potential to transform healthcare analytics, population health management, and drug development. The partnership will also explore next-generation healthcare solutions while supporting healthcare equity. Additionally, Illumina, Inc. has contributed $20 million to Truveta’s Series C round, further supporting the project. This collaboration underscores the importance of combining advanced genomic technologies with extensive clinical data to drive scientific progress and improve patient care.
